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Information on dietary supplements, medications, and other xenobiotics in epidemiologic surveys is usually
obtained from questionnaires and is subject to recall and reporting biases. The authors usedmetabolite data obtained
from hydrogen-1 (or proton) nuclear magnetic resonance (1H NMR) analysis of human urine specimens from the
International Study of Macro-/Micro-Nutrients and Blood Pressure (INTERMAP Study) to validate self-reported
analgesic use. Metabolic profiling of two 24-hour urine specimens per individual was carried out for 4,630 participants
aged 40–59 years from 17 population samples in Japan, China, the United Kingdom, and the United States
(data collection, 1996–1999). 1H NMR-detected acetaminophen and ibuprofen use was low (~4%) among East
Asian population samples and higher (>16%) in Western population samples. In a comparison of self-reported
acetaminophen and ibuprofen use with 1H NMR-detected acetaminophen and ibuprofen metabolites among
496 participants from Chicago, Illinois, and Belfast, Northern Ireland, the overall rate of concordance was 81%–84%;
the rate of underreporting was 15%–17%; and the rate of underdetection was approximately 1%. Comparison of
self-reported unspecified analgesic use with 1H NMR-detected acetaminophen and ibuprofen metabolites among
2,660 Western INTERMAP participants revealed similar levels of concordance and underreporting. Screening for
urinary metabolites of acetaminophen and ibuprofen improved the accuracy of exposure information. This
approach has the potential to reduce recall bias and other biases in epidemiologic studies for a range of substances,
including pharmaceuticals, dietary supplements, and foods.
analgesics, non-narcotic; anti-inflammatory agents, non-steroidal; epidemiologic studies; metabolomics; pharma-
coepidemiology; questionnaires; reproducibility of results
Abbreviations: CI, confidence interval; 1H NMR, hydrogen-1 nuclear magnetic resonance; INTERMAP Study, International Study
of Macro-/Micro-Nutrients and Blood Pressure.
In the United States, acetaminophen is one of the most
commonly used drugs for treating pain, with 29 billion units
of acetaminophen-containing products having been sold to
retail and nonretail pharmacies in 2005 (1). Of the total
US sales, approximately 60% of these products were sold as
over-the-counter medicines (1). Similarly, in the United
Kingdom, use of acetaminophen is high, with annual sales of
approximately 166 tons in 2000 (2). Other analgesics such as
ibuprofen are used commonly in Western countries; for exam-
ple, in the United Kingdom, total ibuprofen sales of 46 tons
were reported in 2000 (2).
Despite endorsement by regulatory bodies of over-the-
counter analgesics as safe and effective for use without a phy-
sician’s prescription, approximately 40% of reported cases of
liver injury in the United States in 2005 were due to over-the-
counter acetaminophen (1). Likewise, recent United Kingdom
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surveys indicate that a high percentage of the population may
be unaware of the risks associated with analgesic use (3, 4).
In one study, 16% of university students surveyed admitted
that they had knowingly exceeded the maximum daily dose
of analgesics (4); the authors of another survey concluded
that patient knowledge is insufficient to ensure safe usage of
acetaminophen (3). Acetaminophen use has been associated
with nephropathy, asthma, and other lung conditions (5–7),
while ibuprofen use has been linked to increased risk of stroke
and cardiovascular events (8, 9). However, some clinical and
observational studies have yielded conflicting results (10–12),
which could be due in part to difficulties in obtaining accurate
information on use of acetaminophen and/or ibuprofen.
Typically in epidemiologic surveys information on dietary
supplements, medications, and other xenobiotics is obtained
from questionnaires, with resultant data being subject to pos-
sible recall and reporting biases. Reported medication use
is sometimes compared with a secondary measure, such as
general practitioner (13) or pharmacy (14, 15) databases, to
validate the information. However, these secondary measures
are themselves subject to incompleteness and coding errors
and often may not include data on use of over-the-counter
medications. Therefore, objective methods are needed to
reduce bias and misclassification.
High-throughput metabonomic screening methods for
biofluids, such as hydrogen-1 (or proton) nuclear magnetic
resonance (1H NMR) spectroscopy and mass spectrometry,
are now being applied in epidemiologic studies (16–18). These
methods can simultaneously detect hundreds of metabolites
related to diet, the gut microbiome, and the xenometabolome,
including low-molecular-weight drug metabolites. Hence, they
offer greater utility and economy than single-substance assay
approaches—for example, approaches for detecting drug
metabolites (19–21) and for assessing adherence to medication
regimens (22).
Acetaminophen, ibuprofen, and their related metabolites
are readily identifiable in 1H NMR urine spectra, and their
spectral signatures are distinctive (see Web Figure 1, which is
posted on the Journal’s Web site (http://aje.oxfordjournals.
org/)) (23–26). Utilizing these features, we recently de-
veloped and validated a method for detecting the presence/
absence of acetaminophen and ibuprofen in human urine
spectra with sensitivity greater than 98% (27). This was
achieved by performing targeted xenometabolome analyses
for acetaminophen and ibuprofen metabolites from untar-
geted 1H NMR urinary spectra previously acquired for par-
ticipants in the International Study of Macro-/Micro-Nutrients
and Blood Pressure (INTERMAP Study). Here we com-
pare acetaminophen and ibuprofen use detected by means
of 1H NMR spectroscopy of urine specimens with self-
reported analgesic use among participants in the INTERMAP
Study.
MATERIALS AND METHODS
Participants and INTERMAP study design
The INTERMAP Study surveyed 4,680 women and men
aged 40–59 years from Japan (4 samples), the People’s Re-
public of China (3 samples), the United Kingdom (2 samples),
and the United States (8 samples) (28). Participants were
randomly recruited from general and occupational populations
in 1996–1999. Each participant made 4 clinic visits, the
first 2 on consecutive days and the second 2 on consecutive
days 3 weeks later, on average. Dietary data were collected at
each visit by a trained interviewer using the in-depth multi-
pass 24-hour recall method. All foods and drinks consumed
in the previous 24 hours, including dietary supplements, were
recorded.
Prior to the first clinic visit, participants were asked to bring
all of their medications with them, and on both the first and
the third clinic visits, participants were asked to name the
medications they were currently taking for high blood pressure
and any other medications they were taking. Each partici-
pant provided 2 timed 24-hour urine collections, with both
the start and the end of each 24-hour urine collection being
done at the research center, between the first and second clinic
visits and the third and fourth clinic visits (Figure 1). Urine
volume was measured, and aliquots were obtained and stored
at20C and then air-freighted on dry ice to the INTERMAP
Central Laboratory (Leuven, Belgium) for urinary biochemis-
try (sodium, potassium, calcium, magnesium, and creatinine)
and amino acid analysis by means of ion-exchange chro-
matography. Frozen aliquots were also sent from Leuven
to Imperial College London for 1H NMR spectroscopy. The
participants’ responses to questions on medication use, ob-
tained during the first and third clinic visits, were subsequently
coded by trained staff into 55 categories according to standard
procedure—for example, yes/no for current use of oral anti-
diabetic, analgesic, or lipid-lowering agents. Names of med-
ications were not entered into the INTERMAP database.
For this report, the specific names of analgesics used
were obtained from the paper records stored for the Belfast,
Northern Ireland (216 of 220 participants) and Chicago,
Illinois (280 of 315 participants) samples. Therefore, for
persons from these 2 Western population samples, it was pos-
sible to directly compare self-reported acetaminophen and
ibuprofen use with urinary 1H NMR-detected acetaminophen
and ibuprofen use. In subsequent analyses, self-reported
analgesic use (yes/no) from the INTERMAP database was
compared with the presence/absence of urinary 1H NMR-
detected acetaminophen and ibuprofen for participants from
all 17 population samples.
1H NMR spectroscopic analysis of urine specimens
Preparation and 1H NMR spectroscopic analysis of INTER-
MAP urine specimens have been described in detail (16).
Briefly, 500 lL of thawed urine specimen was mixed with
250 lL of phosphate buffer (0.2 M disodium hydrogen
phosphate/0.2 M sodium dihydrogen phosphate, pH 7.4
(range, 60.5)) for stabilization of urine, and 75 lL of
sodium 3-trimethylsilyl-(2,2,3,3-2H4)-1-propionate in deute-
rium monoxide solution (final concentration 0.1 mg/mL) was
added for internal calibration at d 0.0. Each specimen was
placed into a 96-well plate and left to stand for 10 minutes
before centrifugation at 1,500 g for 10 minutes to remove
precipitate. Urine specimens were automatically delivered
using the Bruker Efficient Sample Transfer System (Bruker
BioSpin, Karlsruhe, Germany), and conventional 1H NMR
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spectra were acquired using a Bruker Avance 600 spectrom-
eter (Bruker BioSpin, Rheinstetten, Germany) operating at
600.29 MHz in flow-injection mode. A standard 1-dimensional
pulse sequence was used with presaturation of water reso-
nance (recycle delay  90  t1  90  tm  90 acquisi-
tion; XWIN-NMR 3.5; Bruker BioSpin, Karlsruhe, Germany),
with t1 of 2 seconds and tm of 100 ms. For each specimen,
64 free induction decays were collected into 32,000 data
points using a spectral width of 20 ppm and a total repetition
time of 4.8 seconds. The free induction decays were multi-
plied by an exponential weighting function corresponding
to a line broadening of 0.3 Hz, and data were zero-filled to
64,000 data points prior to Fourier transformation.
All 1H NMR spectra were baseline-corrected and phased
using an in-house routine written in MATLAB 7.0.1 (Math-
Works, Natick, Massachusetts). All spectra were referenced
to sodium 3-trimethylsilyl-(2,2,3,3-2H4)-1-propionate auto-
matically, and each spectrum was digitized into 0.01-ppm
spectral regions. The region of the spectra containing the
water and urea resonances (d 4.5–6.4) was removed. Of the
4,680 INTERMAP participants, valid 1H NMR spectra
were not acquired for one of the 2 urine collections for
50 participants, leaving 4,630 persons (9,260 urine spectra)
for the present report.
Multivariate analysis: acetaminophen and ibuprofen
assessment models
Details on the development and validation of the assess-
ment models, based on orthogonal projection to latent structure
discriminant analysis with a Monte Carlo resampling pro-
cedure, have been published (27). Briefly, a subsample of
INTERMAP urine specimens was visually inspected for
the presence or absence of acetaminophen and ibuprofen
metabolites; these spectra were then used to validate statis-
tical models for detection of each analgesic. Optimal models
were constructed on the basis of detailed spectral regions
containing acetaminophen (d 1.84–1.88; d 2.13–2.25; and
d 7.13–7.49) and ibuprofen (d 0.87–0.9; d 1.05–1.09;
d 1.21–1.23; d 1.38–1.48; and d 1.51–1.55) metabolites, each
with a bin size width of 0.01 ppm. For both acetaminophen
and ibuprofen models, spectra were initially normalized to
the spectral regions containing the drug metabolites. Spectra
were then mean-centered prior to further analysis. Based on
the optimal parameters, models for acetaminophen and ibu-
profen showed sensitivity greater than 98% in identifying
urine specimens containing acetaminophen and ibuprofen
metabolites (27). The acetaminophen model was subsequently
applied to 8,436 urine spectra and the ibuprofen model to
8,604 urine spectra, after excluding persons whose urine spec-
imens were used to validate the prediction models. Here, we
apply the model to the whole INTERMAP 1H NMR data set
(9,260 urine spectra) to objectively assess reported analgesic
use based on the presence or absence of urinary metabolites
of acetaminophen and ibuprofen.
Statistical analysis
Initial analyses were performed on data from the Belfast
and Chicago samples. Self-reported current acetaminophen
or ibuprofen use was compared with the presence/absence
of 1H NMR-detected urinary acetaminophen and ibuprofen
metabolites obtained from the prediction models. Rates
of concordance and 95% confidence intervals were calcu-
lated, along with rates of underreporting/underdetection of
these 2 common analgesics, assuming that 1) the presence
of acetaminophen and ibuprofen urinary metabolites reflected
previous-day intake and 2) where participants reported
having used acetaminophen or ibuprofen when metabolites
were not detected in the urine, these self-reports were accu-
rate and indicated underdetection of acetaminophen and ibu-
profen by 1H NMR. Then self-reported questionnaire data on
current analgesic use (yes/no) for all 17 INTERMAP Western
population samples were compared with the presence/
absence of 1H NMR-detected urinary acetaminophen and
ibuprofen metabolites obtained from the prediction models,
by country, gender, and age group. We used v2 tests to assess
intersubgroup differences in the prevalence of analgesic use.
Figure 1. Twenty-four-hour urine collection periods and corresponding self-reported data on analgesic use, International Study of Macro-/Micro-
Nutrients and Blood Pressure, 1996–1999. The white horizontal arrows indicate 24-hour urine collection periods; the gray arrows indicate
corresponding information on self-reported food and medication intake based on visits 1 and 3; and the black arrows indicate corresponding
information on self-reported food intake based on visits 2 and 4 only and no available information on medication intake.
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Table 1. Comparison of Self-Reported Acetaminophen and Ibuprofen Use With Detection of Acetaminophen and/or Ibuprofen Metabolites in Urine Specimens of Belfast and Chicago




Location, Gender, and Age Group, years
Belfast, Northern Ireland (n 5 216) Chicago, Illinois (n 5 280)
Men (n 5 125) Women (n 5 91)
Subtotal (n 5 216)
Men (n 5 138) Women (n 5 142)
Subtotal (n 5 280)
40–49 (n 5 59) 50–59 (n 5 66) 40–49 (n 5 59) 50–59 (n 5 32) 40–49 (n 5 59) 50–59 (n 5 66) 50–59 (n 5 32) 50–59 (n 5 32)
% 95% CI % 95% CI % 95% CI % 95% CI % 95% CI % 95% CI % 95% CI % 95% CI % 95% CI % 95% CI
Concordancea at
both visits
89.8 82.1, 97.5 92.4 86.0, 98.8 74.6 63.4, 85.6 71.9 56.2, 87.4 83.8 78.9, 88.7 84.7 76.4, 93.0 80.3 70.7, 89.8 80.0 70.6, 89.3 79.2 69.7, 88.5 81.1 76.5, 85.7
Underreportingb
At 1 visit onlyc 10.2 2.5, 17.8 7.6 1.2, 13.9 23.7 12.8, 34.5 15.6 3.0, 28.2 13.9 9.3, 18.5 6.9 1.1, 12.8 10.6 3.2, 18.0 11.4 4.0, 18.8 13.9 5.9, 21.8 10.7 7.1, 14.3
At both visits 0 0, 0 0 0, 0 1.7 0, 5.0 6.3 0, 14.6 1.4 0, 2.9 4.2 0, 8.8 6.1 0.3, 11.8 8.6 2.0, 15.1 5.6 0.3, 10.8 6.1 3.3, 8.9
Subtotal 10.2 2.5, 17.8 7.6 1.2, 13.9 25.4 14.3, 36.5 21.9 7.6, 36.1 15.3 10.5, 20.1 11.1 3.9, 18.3 16.7 7.7, 25.6 20.0 10.6, 29.3 19.4 10.3, 28.5 16.8 12.4, 21.2
Underdetectiond
At 1 visit onlyc 0 0, 0 0 0, 0 0 0, 0 6.3 0, 14.6 0.9 0, 2.2 4.2 0, 8.8 0 0, 0 0 0, 0 0 0, 0 1.1 0, 2.3
At both visits 0 0, 0 0 0, 0 0 0, 0 0 0, 0 0 0 0 0, 0 1.5 0, 4.5 0 0, 0 0 0, 0 0.4 0, 1.1
Subtotal 0 0, 0 0 0, 0 0 0, 0 6.3 0, 14.6 0.9 0, 2.2 4.2 0, 8.8 1.5 0, 4.5 0 0, 0 0 0, 0 1.4 0, 2.8
Mixed findingse 0 0, 0 0 0, 0 0 0, 0 0 0, 0 0 0 0 0, 0 1.5 0, 4.5 0 0, 0 1.4 0, 4.1 0.7 0, 1.7
Abbreviation: CI, confidence interval.
a Detection of urinary acetaminophen and/or ibuprofen metabolites matched with self-reported use of acetaminophen and/or ibuprofen.
b Detection of urinary acetaminophen and/or ibuprofen metabolites but no reported use of acetaminophen and/or ibuprofen.
c Indicates concordance for the other visit.
d Reported use of acetaminophen and/or ibuprofen but no detection of urinary acetaminophen and/or ibuprofen metabolites.


































































Acetaminophen and ibuprofen use among INTERMAP
participants from Belfast and Chicago
Among persons who reported analgesic use, the proportion
using acetaminophen and/or ibuprofen was higher in Belfast
than in Chicago for both visits (for the first clinic visit, 46.7%
and 20.7%, respectively; for the third clinic visit, 27.3% and
16.3%). Use of other analgesics was similar for Belfast and
Chicago (for the first clinic visit, 40.0% and 34.5%, re-
spectively; for the third clinic visit, 36.4% and 32.7%), with
aspirin being the most commonly reported alternative anal-
gesic. The proportion of reported analgesic users for whom
the name of the analgesic was not recorded was higher for
Belfast than for Chicago (for the first clinic visit, 13.3% and
44.8%, respectively; for the third clinic visit, 36.4% and
51.0%). Reported analgesic users for whom the name of the
analgesic was not recorded were excluded from comparisons
with 1H NMR-detected urinary acetaminophen and ibuprofen
Table 2. Prevalence of Analgesic Use According to Detection of Urinary Acetaminophen and IbuprofenMetabolites and According to Self-Reports
Among Male Participants, by Country and Age Group, International Study of Macro-/Micro-Nutrients and Blood Pressure, 1996–1999
Source of Data on
Analgesic Use


























No. % No. % No. % No. % No. % No. % No. % No. % No. %
Acetaminophen signals
in 1H NMR urine
spectra
First urine specimen 3 1.0 2 0.7 7 3.3 4 1.9 11 8.3 13 9.8 37 6.9 48 8.7 125 5.4
Second urine
specimen
2 0.7 0 0 5 2.4 4 1.9 10 7.5 14 10.6 42 7.9 51 9.3 128 5.5
First or second urine
specimen
5 1.7 2 0.7 11 5.2 7 3.4 16 12.0 23 17.4 64 12.0 78 14.2 206 8.8
First and second urine
specimens
0 0 0 0 1 0.5 1 0.5 5 3.8 4 3.0 15 2.8 21 3.8 47 2.0
Ibuprofen signals
in 1H NMR urine
spectra
First urine specimen 0 0 1 0.4 1 0.5 0 0 2 1.5 1 0.8 25 4.7 39 7.1 69 3.0
Second urine
specimen
2 0.7 1 0.4 1 0.5 2 1.0 4 3.0 4 3.0 28 5.2 41 7.5 83 3.6
First or second urine
specimen
2 0.7 1 0.4 2 1.0 2 1.0 5 3.8 4 3.0 44 8.2 62 11.3 122 5.2
First and second urine
specimens
0 0 1 0.4 0 0 0 0 1 0.8 1 0.8 9 1.7 18 3.3 30 1.3
Acetaminophen and/or
ibuprofen signals
in 1H NMR urine
spectra
First urine specimen 3 1.0 3 1.1 8 3.8 4 1.9 13 9.8 14 10.6 60 11.2 84 15.3 189 8.1
Second urine
specimen
4 1.4 1 0.4 6 2.9 6 2.9 13 9.8 18 13.6 67 12.5 88 16.0 203 8.7
First or second urine
specimen
7 2.4 3 1.1 13 6.2 9 4.4 20 15.0 27 20.5 99 18.5 131 23.8 309 13.2
First and second urine
specimens
0 0 1 0.4 1 0.5 1 0.5 6 4.5 5 3.8 28 5.2 41 7.5 83 3.6
Self-reported analgesic
use
First clinic visit 2 0.7 4 1.4 3 1.4 5 2.4 10 7.5 15 11.4 42 7.9 87 15.8 168 7.2
Third clinic visit 2 0.7 4 1.4 4 1.9 6 2.9 7 5.3 10 7.6 43 8.0 91 16.5 167 7.1
First or third clinic
visit
4 1.4 6 2.1 7 3.3 11 5.3 13 9.8 15 11.4 58 10.8 114 20.7 228 9.8
First and third clinic
visits
0 0 2 0.7 0 0 0 0 4 3.0 10 7.6 27 5.0 64 11.6 107 4.6
Abbreviation: 1H NMR, hydrogen-1 nuclear magnetic resonance.
352 Loo et al.
Am J Epidemiol. 2012;175(4):348–358
metabolites; therefore, 216 (98.2%) of 220 participants from
Belfast and 280 (88.9%) of 315 participants from Chicago
were available for these analyses.
In comparison of self-reported acetaminophen and/or
ibuprofen data with 1H NMR-detected urinary acetamin-
ophen and/or ibuprofen metabolites (Table 1), overall rates
of concordance were high for both populations: 83.8%
(95% confidence interval (CI): 78.9, 88.7) in Belfast and
81.1% (95% CI: 76.5, 85.7) in Chicago. Concordance rates
were comparable across gender and age groups. Overall rates
of underdetection of acetaminophen and ibuprofen were
low (~1%) and were comparable for both population sam-
ples. Rates of underreporting for both visits were higher in
Chicago than in Belfast (6.1% (95% CI: 3.3, 8.9) and 1.4%
(95% CI: 0, 2.9); P ¼ 0.01). Rates of underreporting at
1 visit only were comparable for the 2 populations: 10.7%
(95% CI: 7.1, 14.3) for Chicago and 13.9% (95% CI: 9.3, 18.5)
for Belfast (P ¼ 0.28).
Table 3. Prevalence of Analgesic Use According to Detection of Urinary Acetaminophen and Ibuprofen Metabolites and According to
Self-Reports Among Female Participants, by Country and Age Group, International Study of Macro-/Micro-Nutrients and Blood Pressure,
1996–1999
Source of Data on
Analgesic Use


























No. % No. % No. % No. % No. % No. % No. % No. % No. %
Acetaminophen signals
in 1H NMR urine
spectra
First urine specimen 7 2.4 8 2.9 5 2.4 7 3.4 19 14.8 18 17.5 62 11.5 73 13.6 199 8.7
Second urine
specimen
8 2.7 4 1.4 6 2.8 3 1.5 17 13.3 22 21.4 54 10.0 78 14.5 192 8.4
First or second urine
specimen
13 4.5 11 4.0 10 4.7 10 4.9 32 25.0 30 29.1 90 16.6 118 21.9 314 13.7
First and second urine
specimens
2 0.7 1 0.4 1 0.5 0 0 4 3.1 10 9.7 26 4.8 33 6.1 77 3.4
Ibuprofen signals
in 1H NMR urine
spectra
First urine specimen 0 0 0 0 0 0 3 1.5 3 2.3 4 3.9 43 7.9 54 10.0 107 4.7
Second urine
specimen
1 0.3 0 0 2 0.9 1 0.5 3 2.3 4 3.9 55 10.2 57 10.6 123 5.4
First or second urine
specimen
1 0.3 0 0 2 0.9 3 1.5 5 3.9 6 5.8 75 13.9 83 15.4 175 7.6
First and second urine
specimens
0 0 0 0 0 0 1 0.5 1 0.8 2 1.9 23 4.3 28 5.2 55 2.4
Acetaminophen and/or
ibuprofen signals
in 1H NMR urine
spectra
First urine specimen 7 2.4 8 2.9 5 2.4 10 4.9 22 17.2 21 20.4 100 18.5 123 22.9 296 12.9
Second urine
specimen
9 3.1 4 1.4 8 3.8 4 2.0 20 15.6 25 24.3 107 19.8 127 23.6 304 13.3
First or second urine
specimen
14 4.8 11 4.0 12 5.7 13 6.4 36 28.1 35 34.0 153 28.3 186 34.6 460 20.1
First and second urine
specimens
2 0.7 1 0.4 1 0.5 1 0.5 6 4.7 11 10.7 54 10.0 64 11.9 140 6.1
Self-reported analgesic
use
First clinic visit 5 1.7 4 1.4 5 2.4 6 2.9 6 4.7 8 7.8 50 9.2 87 16.2 171 7.5
Third clinic visit 2 0.7 2 0.7 6 2.8 14 6.9 7 5.5 11 10.7 51 9.4 79 14.7 172 7.5
First or third clinic
visit
5 1.7 5 1.8 10 4.7 18 8.8 10 7.8 15 14.6 71 13.1 106 19.7 240 10.5
First and third clinic
visits
2 0.7 1 0.4 1 0.5 2 1.0 3 2.3 4 3.9 30 5.5 60 11.2 103 4.5
Abbreviation: 1H NMR, hydrogen-1 nuclear magnetic resonance.
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Unspecified analgesic use among INTERMAP
participants from Japan, China, the United Kingdom,
and the United States
Self-reported analgesic use was similar for men and
women (for the first clinic visit, 7.2% and 7.5%, respectively
(P ¼ 0.73); for the third clinic visit, 7.1% and 7.5%, respec-
tively (P ¼ 0.69)) (Tables 2 and 3). The prediction models
indicated that 644 (7.0%) of 9,260 urine spectra contained
acetaminophen metabolites and 382 (4.1%) contained ibu-
profen metabolites. The prevalence of detected acetaminophen
and ibuprofen metabolites was significantly higher in urine
specimens obtained from Western participants than from urine
specimens obtained from East Asian participants (P< 0.0001),
indicating wider acetaminophen and ibuprofen use among
participants from the United Kingdom and the United States
(overall rate of 16.4% for the first urine collection and
17.5% for the second urine collection; 9.8%–16.0% for men,
15.6%–24.3% for women) than among participants from
China and Japan (overall rate of 4.8% for the first urine col-
lection and 4.2% for the second urine collection; 0.4%–3.8%
for men, 1.4%–4.9% for women). Based on detection of
acetaminophen and ibuprofen metabolites in urinary speci-
mens, the numbers of acetaminophen and ibuprofen users
were mostly higher than the numbers of participants who
reported current use of any analgesic medication, indicating
systematic underreporting of analgesic use. This discrepancy
was more prominent among women than among men.
The prevalence of acetaminophen and ibuprofen use varied
among the Western population samples: Honolulu, Hawaii
(all participants of Japanese ancestry) had the lowest preva-
lence, with 7.8% of urine specimens containing acetaminophen
and/or ibuprofen metabolites for the first urine collection and
9.3% for the second urine collection (Web Table 1). Pittsburgh,
Pennsylvania, and Corpus Christi, Texas (non-Hispanic par-
ticipants) showed the highest prevalence of analgesic use,
with acetaminophen and/or ibuprofen metabolites being de-
tected in more than 20% of the first and second urine collec-
tions. Among Western participants, those aged 50–59 years
had higher acetaminophen and/or ibuprofen use than those
aged 40–49 years (for the first and second urine specimens,
P¼ 0.01 and P¼ 0.006, respectively), and more women used
acetaminophen and/or ibuprofen than men (P< 0.0001 for
both urine specimens).
Self-reported data on analgesic use (Web Table 2) were
similar to urinary data, with Honolulu showing the lowest
Table 4. Comparison of Self-Reported Analgesic Use With Detection of Urinary Acetaminophen and/or Ibuprofen Metabolites for Participants at
Western Locations, International Study of Macro-/Micro-Nutrients and Blood Pressure, 1996–1999
Country and Location
















% 95% CI % 95% CI % 95% CI % 95% CI % 95% CI
Matched urinary data
and self-reported
data at both visits





but participant did not
report analgesic use
At one visit onlya 13.6 9.1, 18.1 19.9 15.2, 24.6 13.8 9.8, 17.9 8.9 5.7, 12.0 7.8 4.5, 11.0
At both visits 1.4 0, 2.9 3.3 1.2, 5.4 7.3 4.2, 10.3 4.8 2.4, 7.1 3.5 1.3, 5.7







At one visit onlya 3.2 0.9, 5.5 4.3 1.9, 6.8 3.6 1.4, 5.9 9.2 6.1, 12.3 2.3 0.5, 4.2
At both visits 1.8 0.1, 3.6 1.8 0.2, 3.4 3.6 1.4, 5.9 7.3 4.4, 10.1 1.2 0, 2.5
Subtotal 5.0 2.1, 7.9 6.1 3.3, 9.0 7.2 4.2, 10.3 16.5 12.4, 20.6 3.5 1.3, 5.7
Mismatch of information




0 0, 0 0.7 0, 1.7 0.4 0, 1.1 2.2 0.6, 3.9 0 0, 0
Table continues
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proportion of reported analgesic users (3.5% for both the
first and third visits). Prevalences of self-reported analgesic
use at the first and third visits were greater than 15% for the
Chicago, Minneapolis (Minnesota), Pittsburgh, and Corpus
Christi (non-Hispanic) samples (Web Table 2). High-level
concordance (>60%) was observed between self-reported
analgesic use and 1H NMR-detected urinary acetaminophen
and/or ibuprofen metabolites (Table 4) for all Western popu-
lation samples, with concordance being lowest for Pittsburgh
(60.6%, 95% CI: 54.6, 66.5) and an overall concordance of
70.5% (95% CI: 68.7, 72.2).
Three main types of discrepancy were also observed.
The first group was persons who did not report use of any
analgesics but for whom acetaminophen and/or ibuprofen
metabolites were detected in the urine specimen at 1 or more
visits (putative underreporters) (19.4%, 95% CI: 17.9, 20.9).
This discrepancy varied across population samples, being
lowest for Honolulu (11.3%, 95% CI: 7.4, 15.1) and highest
for Jackson, Mississippi (27.2%, 95% CI: 21.8, 32.6). Jackson
(7.3%, 95% CI: 4.1, 10.4) and Baltimore, Maryland (7.3%,
95% CI: 4.2, 10.3) showed the highest rates of potential
underreporting at both visits. Overall, 129 persons (4.9%,
95% CI: 4.0, 5.7) underreported analgesic use at both visits,
while 387 (14.5%, 95% CI: 13.2, 15.9) underreported anal-
gesic use at 1 visit only. The second group was persons who
reported analgesic use but for whom acetaminophen and/or
ibuprofen metabolites were not detected in urine specimens
(due to putative underdetection of acetaminophen/ibuprofen
by 1H NMR, use of an alternative analgesic not detected by the
prediction models, or time-frame differences in urine col-
lection and self-reported data). The overall rate for this dis-
crepancy was 9.4% (95% CI: 8.3, 10.5), and rates were higher
for Chicago (16.5%, 95% CI: 12.4, 20.6), Pittsburgh (15.8%,
95% CI: 11.3, 20.2), Minneapolis (13.5%, 95% CI: 9.3, 17.6),
and Corpus Christi (non-Hispanics) (11.5%, 95% CI: 7.7, 15.2).
The third group was persons with a mixture of the above
two types of discrepancy—for example, a person who reported
use of an analgesic at the first visit but not the third visit, but
the 1H NMR urine spectra revealed the presence of either
acetaminophen and/or ibuprofen or both metabolites in the
second urine specimen though not the first. The percentage in
this group was typically low (~2% or less) across all Western
population samples, being highest in the Chicago sample




















% 95% CI % 95% CI % 95% CI % 95% CI % 95% CI % 95% CI
67.4 61.7, 73.1 70.0 64.4, 75.5 60.6 54.6, 66.5 69.7 64.2, 75.2 65.1 59.5, 70.8 70.5 68.7, 72.2
19.9 15.0, 24.7 11.5 7.7, 15.4 17.3 12.7, 21.9 15.6 11.3, 20.0 17.4 12.8, 21.9 14.5 13.2, 15.9
7.3 4.1, 10.4 4.2 1.8, 6.7 5.8 2.9, 8.6 4.9 2.3, 7.4 5.6 2.8, 8.3 4.9 4.0, 5.7
27.2 21.8, 32.6 15.7 11.3, 20.1 23.1 18.0, 28.3 20.5 15.6, 25.3 23.0 17.9, 27.9 19.4 17.9, 20.9
1.9 0.3, 3.6 6.2 3.2, 9.1 10.8 7.0, 14.5 6.3 3.4, 9.3 7.8 4.6, 10.9 5.7 4.8, 6.6
1.5 0, 3.0 7.3 4.1, 10.4 5.0 2.4, 7.7 2.6 0.7, 4.5 3.7 1.5, 6.0 3.7 3.0, 4.4
3.4 1.2, 5.7 13.5 9.3, 17.6 15.8 11.3, 20.2 8.9 5.5, 12.3 11.5 7.7, 15.2 9.4 8.3, 10.5
1.9 0.3, 3.6 0.8 0, 1.8 0.4 0, 1.1 0.8 0, 1.8 0.4 0, 1.1 0.8 0.5, 1.1
Abbreviation: CI, confidence interval.
a Indicates concordance for another visit.
Table 4. Continued
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For East Asian participants overall, both urinary levels and
self-reported analgesic use were low (~4%) and gender/age
differences in analgesic use were not observed (Web Tables 3
and 4). Comparisons of reported analgesic use and 1H NMR-
detected urinary acetaminophen and ibuprofen metabolites
were not made for the East Asian samples because of a low
prevalence of analgesic use in those population samples.
DISCUSSION
Our findings showed the efficacy of a novel method for ob-
jective assessment of xenobiotic use, to validate epidemiologic
questionnaire data, via 1H NMR spectroscopy of urine spec-
imens. We found high levels of concordance for self-reported
acetaminophen and/or ibuprofen use with urinary acetamin-
ophen and/or ibuprofen metabolites detected by 1H NMR
spectroscopy. Although detailed self-reported acetaminophen
and ibuprofen data were available only for 496 Belfast and
Chicago participants, confidence intervals for concordance,
underreporting, and underdetection showed acceptable levels
of precision. Furthermore, similar levels of concordance and
underreporting were observed with self-reported unspecified
analgesic use among 2,660 Western INTERMAP participants.
Detection of underreporting was generally higher in women
than in men. Urinary rates of acetaminophen/ibuprofen de-
tection were mostly higher than rates of self-reported analgesic
use, indicating an overall rate of underreporting of analgesic
use among Western INTERMAP participants of approx-
imately 20%. Underreporting at both clinic visits, which
were made on average 3 weeks apart, was detected for
5% of Western participants. Such ‘‘serial’’ underreporting
could potentially reflect intentional underreporting by the
participant. Unintentional underreporting, which could occur
at one or both visits, could be due to memory lapse and/or
ingestion of analgesics after the clinic visit but during the 24-
hour urine collection period. It is likely that the scale of
underreporting of total analgesic use is greater, since only
acetaminophen and ibuprofen metabolites were detected by
the present method.
For 9.4% of Western participants, analgesic use was
reported but acetaminophen and/or ibuprofen metabolites were
not detected in urine specimens. This discrepancy may have
been due to underdetection by 1H NMR of acetaminophen/
ibuprofen metabolites in the urinary spectra. However, this
is unlikely to have been a major factor, since we previously
demonstrated that the acetaminophen and ibuprofen predic-
tion models each had a sensitivity greater than 98% (27);
furthermore, detailed data on analgesic use from Belfast and
Chicago participants indicated an underdetection rate of
approximately 1%. It is also possible that the rate of analgesic
use was underestimated by 1H NMR because of differences in
the time frame between collection of self-reported data
and collection of urine specimens. Both acetaminophen and
ibuprofen are rapidly excreted in the urine after oral ingestion,
and the elimination half-lives are approximately 4 hours and
2 hours, respectively (29). Thus, analgesics taken during
the 24 hours prior to the first and third clinic visits could
have been reported by the participants but fully excreted
before the start of the 24-hour urine collections. It is likely
that the major contributor to the apparent ‘‘underdetection’’
by 1H NMR is self-reported use of common alternative an-
algesics not detected by the current prediction models. This
is supported by our detailed data from Belfast and Chicago,
where alternative analgesics (predominantly aspirin) ac-
counted for approximately one-third of total reported an-
algesic use. Given these limitations, we can assume that the
overall concordance between reported and 1H NMR-detected
acetaminophen/ibuprofen use for Western participants will be
higher than the 70% observed between unspecified analgesic
use and 1H NMR-detected acetaminophen/ibuprofen.
Our data indicate low rates of analgesic use in East Asian
population samples compared with Western samples and
higher rates in older participants and women. The latter finding
is consistent with other epidemiologic data, including data
from the Third National Health and Nutrition Examination
Survey (30) and the Tromsø Study (31). Observed gender and
age differences in analgesic use probably reflect gender- and
age-related differences in disease rates—for example, a higher
prevalence of rheumatoid arthritis in women and higher
prevalences of both rheumatoid arthritis and osteoarthritis
in older persons (32, 33). The level of concordance observed
here was similar to that in other studies, such as studies com-
paring self-reported questionnaire data with electronic mon-
itoring systems (34, 35) and general practitioner records (36).
However, our method offers several advantages compared
with self-report validation tools that rely on pharmacy or gen-
eral practitioner records (34–40). First, pharmacy or general
practitioner records may be prone to incomplete information,
particularly if patients use multiple pharmacies or physicians.
Second, analgesics purchased over the counter, such as acet-
aminophen and ibuprofen, may not be recorded in general
practitioner/pharmacy databases. Third, general practitioner
records document prescriptions only; the prescriptions may
or may not have been filled (41–43). Even if a patient filled
the prescription, he or she may not have actually taken the
drug; nonadherence to medication regimens has been widely
reported (44–46). In contrast, urinary 1H NMR data reflect
actual ingestion of the analgesic.
To our knowledge, our study provides the only objective
data on population exposure to acetaminophen and ibuprofen
currently available. We were able to account for discrep-
ancies with self-reported unspecified analgesic data, and this
approach could be used in future studies to validate self-
reported analgesic data and improve exposure classification.
Moreover, the generality of metabolic profiling methods makes
it more efficient than most biologic assays, which tend to be
calibrated for the measurement of specific biochemical com-
pounds. The approach demonstrated here could be adapted
for validation of self-reported dietary supplements and food
consumption. Using a 1H NMR-based approach, Heinzmann
et al. (47) identified proline betaine as a biomarker of self-
reported citrus fruit consumption. Others have applied mass
spectrometry-based approaches to nutritional biomarker
discovery (48, 49).
In terms of a general metabonomics-based biomarker
discovery strategy, we recommend global untargeted 1H NMR
spectroscopy or untargeted mass spectrometry with multi-
variate chemometric analyses for hypothesis generation, com-
plemented as necessary by targeted mass spectrometry or other
biochemical analyses for validation. This approach could be
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used to validate self-reported data on drug use or to retrospec-
tively estimate the prevalence of (for example) analgesic use,
in population samples where urine specimens were collected
but data on analgesic use were not available. It is essential for
validation studies that the time frames of self-reported data
and urine specimens be aligned appropriately to account for
the excretion rates of the biomarker metabolites.
In conclusion, in our large-scale, multinational epide-
miologic study, we demonstrated the efficacy of an objec-
tive 1H NMR-based method for validation of self-reported
data on analgesic use, detecting an underreporting rate of
approximately 15% or more. The analytical strategy offers
benefits over traditional methods for validating drug-use
data (e.g., general practitioner or pharmacy records) and
may be applied to a wide range of xenobiotics, including
pharmaceuticals, dietary supplements, and foods.
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